Clinical trial
Phase 3
Interventional
Ages 18 and up
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Run by Viking Therapeutics, Inc. · NCT07104383 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-07-01.
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1100 (estimated) |
| Sponsor | Viking Therapeutics, Inc. Industry-sponsored |
| Drugs / interventions | VK2735 |
| Locations | 127 sites (Puerto Rico, United States) |
| Trial ID | NCT07104383 on ClinicalTrials.gov |
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥27 kg/m2 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists Exclusion Criteria: 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening) 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line) 5. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM) 6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL 7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization 8. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment 9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 10. History of acute or chronic pancreatitis 11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening
Where it's running
-
Viking Clinical Site #2037
Birmingham, Alabama, United States -
Viking Clinical Site #2064
Birmingham, Alabama, United States -
Viking Clinical Site #2128
Huntsville, Alabama, United States -
Viking Clinical Site #2005
Chandler, Arizona, United States -
Viking Clinical Site #2017
Flagstaff, Arizona, United States -
Viking Clinical Site #2018
Peoria, Arizona, United States
Show 44 more locations
-
Viking Clinical Site #2135
Scottsdale, Arizona, United States -
Viking Clinical Site #2019
Tucson, Arizona, United States -
Viking Clinical Site #2036
Little Rock, Arkansas, United States -
Viking Clinical Site #2071
Chula Vista, California, United States -
Viking Clinical Site #2070
Escondido, California, United States -
Viking Clinical Site #2054
Huntington Park, California, United States -
Viking Clinical Site #2014
Lake Forest, California, United States -
Viking Clinical Site #2129
Lemon Grove, California, United States -
Viking Clinical Site #2051
Lincoln, California, United States -
Viking Clinical Site #2050
Long Beach, California, United States -
Viking Clinical Site #2078
Manteca, California, United States -
Viking Clinical Site #2053
Montclair, California, United States -
Viking Clinical Site #2068
Panorama City, California, United States -
Viking Clinical Site #2132
Rolling Hills Estates, California, United States -
Viking Clinical Site #2131
San Diego, California, United States -
Viking Clinical Site #2052
Spring Valley, California, United States -
Viking Clinical Site #2109
Tustin, California, United States -
Viking Clinical Site #2067
Van Nuys, California, United States -
Viking Clinical Site #2079
Walnut Creek, California, United States -
Viking Clinical Site #2119
Denver, Colorado, United States -
Viking Clinical Site #2013
Clearwater, Florida, United States -
Viking Clinical Site #2121
Clearwater, Florida, United States -
Viking Clinical Site #2003
Cooper City, Florida, United States -
Viking Clinical Site #2112
DeLand, Florida, United States -
Viking Clinical Site #2107
Delray Beach, Florida, United States -
Viking Clinical Site #2083
Fort Myers, Florida, United States -
Viking Clinical Site #2058
Jacksonville, Florida, United States -
Viking Clinical Site #2076
Lakeland, Florida, United States -
Viking Clinical Site #2060
Lakewood Rch, Florida, United States -
Viking Clinical Site #2117
Miami, Florida, United States -
Viking Clinical Site #2012
Ocoee, Florida, United States -
Viking Clinical Site #2056
Palmetto Bay, Florida, United States -
Viking Clinical Site #2011
Port Orange, Florida, United States -
Viking Clinical Site #2057
West Palm Beach, Florida, United States -
Viking Clinical Site #2116
Atlanta, Georgia, United States -
Viking Clinical Site #2030
Columbus, Georgia, United States -
Viking Clinical Site #2120
Rincon, Georgia, United States -
Viking Clinical Site #2093
Savannah, Georgia, United States -
Viking Clinical Site #2025
Woodstock, Georgia, United States -
Viking Clinical Site #2062
Honolulu, Hawaii, United States -
Viking Clinical Site #2080
Meridian, Idaho, United States -
Viking Clinical Site #2006
Chicago, Illinois, United States -
Viking Clinical Site #2146
Indianapolis, Indiana, United States -
Viking Clinical Site #2127
Valparaiso, Indiana, United States
+77 more sites. See ClinicalTrials.gov for the full list.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.